Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 9/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | S100B | P04271 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611931 | 0.85 | NR1H4 (0.60) | ANO1LMNANR1H4HDAC8MEN1 | |
| SCHEMBL13701695 | 0.83 | HDAC8 (0.64) | ANO1LMNANR1H4HDAC8MAPT | |
| SCHEMBL13701684 | 0.82 | BCAT2 (0.51) | ANO1LMNANR1H4HDAC8MEN1 | |
| SCHEMBL13611927 | 0.81 | S100B (0.47) | ANO1MEN1KMT2AMAPTS100B | |
| SCHEMBL13701677 | 0.80 | KDM4E (0.50) | ANO1LMNAHDAC8MEN1KMT2A | |
| SCHEMBL13701634 | 0.79 | MEN1 (0.58) | ANO1LMNAHDAC8MEN1KMT2A | |
| SCHEMBL21249304 | 0.79 | LMNA (0.58) | ANO1HDAC6LMNAHDAC8KMT2A | |
| SCHEMBL13701631 | 0.78 | HDAC8 (0.54) | HDAC6LMNAHDAC8KMT2A | |
| SCHEMBL13701654 | 0.78 | RXRA (0.59) | LMNANR1H4HDAC8MEN1KMT2A | |
| SCHEMBL24454658 | 0.78 | ALDH1A1 (0.50) | KDM1AHDAC1HDAC6PTPN5HSD17B14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | ANO1 4532/4885KDM1A 1849/4885HDAC1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.